Available Technologies
# of Displayed Technologies: 6 / 6
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Discovery of a novel CD34(+) natural killer precursor population in human lymph nodes
TS-037651 — Ohio State University researchers have discovered novel subset of human CD34 (+) hematopoietic precursor cells and generated a method of isolating them.
Natural killer (NK) cells are a type of lymphocyte that plays a role in the immune system. These cells can react against and destroy another cell without prior sensitization to it. The role of NK cells in tumor activity is known, but recent research has also linked them to other immune disease con…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Becknell, Michael; Freud, Aharon
- Licensing Officer: Schworer, Adam
Combination Agent Approach for Improved Expansion and Mobilization of Hematopoietic Stem Cells
TS-037629 — Combined treatment of plerixafor and Flt3L better mobilize stem cells and do not exacerbate graft-versus-host disease following transplatation.
Hematopoietic stem cell transplantation (HSCT) is used in patients with hematologic malignancies resulting from irradiation and graft-versus-tumor effects. However, patients who undergone HSCT may suffer complications such as graft-versus-host disease (GVHD), infection, and relapse. The most commo…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Devine, Steven
- Licensing Officer: Taysavang, Panya
Potential uses of IgG Fc for treating human diseases
TS-036778 —
Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
- College: College of Medicine (COM)
- Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
